Encouraging findings emerge from an interim analysis of the ECHO Phase III trial, indicating that AstraZeneca’s Calquence (acalabrutinib), when paired with standard-of-care chemoimmunotherapy—bendamustine and rituximab—achieved a significant improvement in progression-free survival (PFS) compared to standard treatment in previously untreated adults…
Novo Nordisk’s Q1 2024 Performance Highlights Growth and Expansion Novo Nordisk, a global healthcare company focusing on diabetes and other serious chronic diseases, has reported robust financial results for the first three months of 2024. Operating profit surged by 27%…
The DESTINY-Breast06 Phase III trial yielded encouraging results, demonstrating the effectiveness of Enhertu (trastuzumab deruxtecan) in improving progression-free survival (PFS) significantly and meaningfully compared to standard chemotherapy. This positive outcome was observed in patients with HR-positive, HER2-low metastatic breast cancer…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has revealed findings from its Phase 3 trial, STRIDE-10, assessing V116, the company’s advanced 21-valent pneumococcal conjugate vaccine designed for adults. The announcement took place at…
AbbVie (NYSE: ABBV) has released its financial results for the first quarter ending March 31, 2024. Richard A. Gonzalez, the chairman and CEO of AbbVie, expressed satisfaction with the company’s strong performance, highlighting their consistent operational execution. He also commended…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled the launch of WHAT THE C@H?!, an educational initiative designed to address the information gap surrounding congenital adrenal hyperplasia (CAH) and acknowledge the challenges faced by the community in managing this condition. “We…
CVS Health® (NYSE: CVS) revealed today a significant investment of $19.2 million, facilitated via Boston Financial, earmarked for the construction of 85 new affordable housing units in Arvada, Colorado. This initiative, executed in partnership with Family Tree and BlueLine Development,…
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has unveiled positive top-line results from its Phase 2 SAVITRI™ trial. This study, employing a randomized, double-blind, and placebo-controlled design, evaluated the efficacy and safety of NBI-1065845 in adult patients grappling with major depressive disorder…
Pfizer Inc. (NYSE: PFE) has received approval from the European Commission (EC) for EMBLAVEO® (aztreonam-avibactam), expanding treatment options for adult patients facing complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including…
GSK plc (LSE/NYSE: GSK) has unveiled encouraging outcomes from the pivotal EAGLE-1 phase III trial concerning gepotidacin, a prospective first-in-class oral antibiotic offering a novel approach to combat uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. These findings are slated…
AbbVie (NYSE: ABBV) has announced encouraging findings from its Phase 3 trial, SELECT-GCA, showcasing positive top-line results. The trial, conducted across multiple centers, employed a randomized, double-blind, placebo-controlled design. It investigated the efficacy of upadacitinib (marketed as RINVOQ®) in combination…
Cerevel Therapeutics (Nasdaq: CERE) has released encouraging findings from its pivotal Phase 3 TEMPO-3 trial for tavapadon, a unique D1/D5 receptor partial agonist investigated as a once-daily treatment for Parkinson’s disease. This trial assessed tavapadon’s efficacy, safety, and tolerability as…